3 Biotech Stocks With Major Potential Catalysts in July

Neurocrine Biosciences (NASDAQ: NBIX), along with partner AbbVie(NYSE: ABBV), Progenics Pharmaceuticals (NASDAQ: PGNX), and Insys Pharmaceuticals (NASDAQ: INSY) await major approval decisions by the U.S. Food and Drug Administration (FDA). Here's what you need to know about the potential catalysts for these biotech stocks.